BP 897, a Selective Dopamine D3 Receptor Ligand with Therapeutic Potential for the Treatment of Cocaine-Addiction-Reference-Cited by-同舟云学术

BP 897, a Selective Dopamine D3 Receptor Ligand with Therapeutic Potential for the Treatment of Cocaine-Addiction

Published:2006-06-07 Issue:2 Volume:9 Page:141-158
ISSN:1080-563X
Container-title:CNS Drug Reviews
language:en
Short-container-title:

Author:

Garcia-Ladona F. J.,Cox B. F.

Publisher

Wiley

Subject

Pharmacology,Neuropsychology and Physiological Psychology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1527-3458.2003.tb00246.x/fullpdf

Reference104 articles.

1. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice;Accili;Proc Natl Acad Sci USA,1996

2. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands;Acri;Eur J Pharmacol,1995

3. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194;Audinot;J Pharmacol Exp Ther,1998

4. A dopamine D3 receptor partial agonist blocks the expression of conditioned activity;Aujla;Neuroreport,2002

5. Food intake, neuroendocrine and temperature effects of 8-OHDPAT in the rat;Aulakh;Eur J Pharmacol,1988

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H3 and dopamine D3 receptors;Bioorganic & Medicinal Chemistry;2023-01

2. Synthesis, in silico, and in vitro studies of novel dopamine D 2 and D 3 receptor ligands;Archiv der Pharmazie;2021-02-22

3. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders;Biomolecules;2021-01-14

4. (±)VK4‐40, a novel dopamine D 3 receptor partial agonist, attenuates cocaine reward and relapse in rodents;British Journal of Pharmacology;2020-09-17

5. Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges;Neuroscience & Biobehavioral Reviews;2020-07